ATE532073T1 - Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels - Google Patents
Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegelsInfo
- Publication number
- ATE532073T1 ATE532073T1 AT04765681T AT04765681T ATE532073T1 AT E532073 T1 ATE532073 T1 AT E532073T1 AT 04765681 T AT04765681 T AT 04765681T AT 04765681 T AT04765681 T AT 04765681T AT E532073 T1 ATE532073 T1 AT E532073T1
- Authority
- AT
- Austria
- Prior art keywords
- risk
- subject
- determining
- galectin
- thrombospondin
- Prior art date
Links
- 102000000802 Galectin 3 Human genes 0.000 title abstract 2
- 108010001517 Galectin 3 Proteins 0.000 title abstract 2
- 102100029529 Thrombospondin-2 Human genes 0.000 title abstract 2
- 108010060887 thrombospondin 2 Proteins 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title 1
- 239000003550 marker Substances 0.000 abstract 3
- 230000009787 cardiac fibrosis Effects 0.000 abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078161A EP1522857A1 (en) | 2003-10-09 | 2003-10-09 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| PCT/EP2004/010879 WO2005040817A1 (en) | 2003-10-09 | 2004-09-27 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE532073T1 true ATE532073T1 (de) | 2011-11-15 |
Family
ID=34306912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04765681T ATE532073T1 (de) | 2003-10-09 | 2004-09-27 | Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7888137B2 (enExample) |
| EP (4) | EP1522857A1 (enExample) |
| JP (5) | JP4840744B2 (enExample) |
| CN (2) | CN102998458B (enExample) |
| AT (1) | ATE532073T1 (enExample) |
| AU (2) | AU2004284496C1 (enExample) |
| CA (2) | CA2542033C (enExample) |
| CY (2) | CY1112359T1 (enExample) |
| DK (2) | DK1682907T3 (enExample) |
| ES (2) | ES2377012T3 (enExample) |
| PL (2) | PL2317324T3 (enExample) |
| PT (2) | PT2317324E (enExample) |
| SI (2) | SI2317324T1 (enExample) |
| WO (1) | WO2005040817A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| US8153376B2 (en) | 2006-09-25 | 2012-04-10 | Universiteit Maastricht | Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
| EP2109688A4 (en) * | 2007-01-23 | 2010-02-17 | Univ Virginia | GALECTIN-3 BINDING PROTEIN AS BIOMARKER FOR HEART CIRCULATION DISEASES |
| AU2008302489A1 (en) * | 2007-09-17 | 2009-03-26 | Bg Medicine, Inc. | Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione |
| CA2742265C (en) * | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| CA2771706A1 (en) * | 2009-08-25 | 2011-03-17 | Bg Medicine, Inc. | Galectin-3 and cardiac resynchronization therapy |
| WO2012003475A1 (en) | 2010-07-02 | 2012-01-05 | Bg Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| WO2012053305A1 (ja) * | 2010-10-18 | 2012-04-26 | 岐阜市 | 筋萎縮性側索硬化症マーカー及びその利用 |
| EP2460890A1 (en) | 2010-12-01 | 2012-06-06 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases |
| CA2825954A1 (en) * | 2011-01-31 | 2012-08-09 | Bg Medicine, Inc. | Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome |
| US8728742B2 (en) | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
| RU2545859C1 (ru) * | 2011-12-08 | 2015-04-10 | Исаак ЭЛИАС | Уменьшение уровней галектина-3 посредством плазмафереза |
| WO2014052803A2 (en) * | 2012-09-27 | 2014-04-03 | Siemens Healthcare Diagnostics Inc. | Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension |
| JP6366598B2 (ja) * | 2012-11-15 | 2018-08-01 | タフツ ユニバーシティー | ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット |
| CA2973653A1 (en) | 2015-01-18 | 2016-07-21 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker |
| WO2016190443A1 (ja) * | 2015-05-28 | 2016-12-01 | 京セラ株式会社 | 切削工具 |
| CN112553335A (zh) * | 2020-12-17 | 2021-03-26 | 核工业总医院 | 肾细胞癌生物标志物及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632901A (en) | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US20010051350A1 (en) | 1995-05-02 | 2001-12-13 | Albert Nazareth | Diagnostic detection device and method |
| BE1010935A7 (nl) * | 1997-02-19 | 1999-03-02 | Delanghe Joris Richard Siegfri | Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen. |
| US6210976B1 (en) | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| IL134880A0 (en) * | 1997-09-05 | 2001-05-20 | Univ Southern Australia | A method of diagnosis |
| US20060166276A1 (en) * | 1997-09-05 | 2006-07-27 | Lung Health Diagnostics Pty Ltd | Method of diagnosis and agents useful for same |
| CA2306751C (en) * | 1997-10-24 | 2006-12-12 | Shionogi & Co., Ltd. | Method for inhibiting degradation of natriuretic peptides and improved method for measuring natgriuretic peptides with the use of the same |
| DE69932235T2 (de) * | 1998-04-02 | 2007-06-14 | Genentech, Inc., South San Francisco | Behandlung von herzhypertrophie |
| HU228625B1 (en) * | 1999-01-29 | 2013-04-29 | Roche Diagnostics Gmbh | Method of identifying n-terminal probnp |
| EP1153301A1 (en) * | 1999-02-19 | 2001-11-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for arterial wall disruptive disorders |
| JP2003507076A (ja) * | 1999-08-20 | 2003-02-25 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５ |
| AU3087801A (en) | 2000-02-04 | 2001-08-14 | Molecular Dynamics Inc | Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells |
| EP1358347A2 (en) | 2000-04-05 | 2003-11-05 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| KR100395254B1 (ko) | 2000-10-30 | 2003-08-21 | (주)자리타 바이오텍 | 종양 발생 예측 키트 |
| AU2002218026A1 (en) * | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US20030166017A1 (en) * | 2000-11-09 | 2003-09-04 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease |
| CA2431861A1 (en) * | 2000-12-08 | 2002-06-13 | Curagen Corporation | Method of detecting and treating tuberous sclerosis complex associated disorders |
| JP4035562B2 (ja) * | 2001-01-31 | 2008-01-23 | 国立大学法人富山大学 | ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット |
| CA2441086A1 (en) | 2001-03-19 | 2002-09-26 | Wisconsin Alumni Research Foundation | Identification of gene expression alterations underlying the aging process in mammals |
| US20060019235A1 (en) | 2001-07-02 | 2006-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular and functional profiling using a cellular microarray |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US20030099958A1 (en) * | 2001-09-05 | 2003-05-29 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
| GB0124145D0 (en) | 2001-10-08 | 2001-11-28 | Bayer Ag | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease |
| US20060141493A1 (en) | 2001-11-09 | 2006-06-29 | Duke University Office Of Science And Technology | Atherosclerotic phenotype determinative genes and methods for using the same |
| CA2483105C (en) * | 2002-05-13 | 2011-05-10 | Arexis Ab | Autoimmune conditions and nadph oxidase defects |
| US20050170528A1 (en) | 2002-10-24 | 2005-08-04 | Mike West | Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications |
| AU2003298689A1 (en) | 2002-11-21 | 2004-06-18 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| EP1431399A1 (en) * | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| US6889083B2 (en) | 2003-04-21 | 2005-05-03 | Medtronic, Inc. | Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes |
| US20070105105A1 (en) | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| WO2004111654A2 (en) | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| EP1560025A3 (en) * | 2003-10-03 | 2011-09-07 | F. Hoffmann-La Roche AG | Specific markers for diabetes |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| DE10347436B4 (de) | 2003-10-13 | 2007-08-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP) |
| US20060019890A1 (en) | 2004-01-15 | 2006-01-26 | Kapoun Ann M | Method for treating cardiac remodeling following myocardial injury |
| WO2006026074A2 (en) | 2004-08-04 | 2006-03-09 | Duke University | Atherosclerotic phenotype determinative genes and methods for using the same |
| WO2006083986A2 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services | Biomarkers for tissue status |
| WO2006102497A2 (en) | 2005-03-22 | 2006-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease |
| US7632634B2 (en) | 2005-04-15 | 2009-12-15 | University Of Maryland Biotechnology Institute | Method and assay for early diagnosis of prostate cancer |
| US9592970B2 (en) | 2008-07-17 | 2017-03-14 | Toby D. Henderson | Robotic gantry with end effector for product lifting |
| CA2742265C (en) | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| CA2771706A1 (en) | 2009-08-25 | 2011-03-17 | Bg Medicine, Inc. | Galectin-3 and cardiac resynchronization therapy |
-
2003
- 2003-10-09 EP EP03078161A patent/EP1522857A1/en not_active Withdrawn
-
2004
- 2004-09-27 AU AU2004284496A patent/AU2004284496C1/en not_active Ceased
- 2004-09-27 WO PCT/EP2004/010879 patent/WO2005040817A1/en not_active Ceased
- 2004-09-27 EP EP04765681A patent/EP1682907B1/en not_active Expired - Lifetime
- 2004-09-27 DK DK04765681.4T patent/DK1682907T3/da active
- 2004-09-27 ES ES04765681T patent/ES2377012T3/es not_active Expired - Lifetime
- 2004-09-27 SI SI200432221T patent/SI2317324T1/sl unknown
- 2004-09-27 ES ES10186331T patent/ES2530567T3/es not_active Expired - Lifetime
- 2004-09-27 CA CA2542033A patent/CA2542033C/en not_active Expired - Lifetime
- 2004-09-27 JP JP2006530040A patent/JP4840744B2/ja not_active Expired - Fee Related
- 2004-09-27 PT PT101863314T patent/PT2317324E/pt unknown
- 2004-09-27 PL PL10186331T patent/PL2317324T3/pl unknown
- 2004-09-27 CA CA2842308A patent/CA2842308A1/en not_active Abandoned
- 2004-09-27 PT PT04765681T patent/PT1682907E/pt unknown
- 2004-09-27 EP EP14192739.2A patent/EP2919012A1/en not_active Withdrawn
- 2004-09-27 SI SI200431813T patent/SI1682907T1/sl unknown
- 2004-09-27 PL PL04765681T patent/PL1682907T3/pl unknown
- 2004-09-27 AT AT04765681T patent/ATE532073T1/de active
- 2004-09-27 CN CN201210321227.7A patent/CN102998458B/zh not_active Expired - Fee Related
- 2004-09-27 DK DK10186331.4T patent/DK2317324T3/en active
- 2004-09-27 CN CN2004800332637A patent/CN1879022B/zh not_active Expired - Fee Related
- 2004-09-27 US US10/575,745 patent/US7888137B2/en active Active
- 2004-09-27 EP EP10186331.4A patent/EP2317324B1/en not_active Expired - Lifetime
-
2009
- 2009-10-19 AU AU2009227844A patent/AU2009227844B2/en not_active Ceased
-
2010
- 2010-07-26 JP JP2010167334A patent/JP2010279378A/ja not_active Withdrawn
- 2010-10-28 US US12/914,329 patent/US8084276B2/en not_active Expired - Fee Related
-
2011
- 2011-04-12 JP JP2011088342A patent/JP5580774B2/ja not_active Expired - Lifetime
- 2011-11-23 US US13/304,145 patent/US20120220532A1/en not_active Abandoned
-
2012
- 2012-02-01 CY CY20121100108T patent/CY1112359T1/el unknown
-
2013
- 2013-03-08 US US13/791,350 patent/US20130189716A1/en not_active Abandoned
-
2014
- 2014-02-06 JP JP2014021394A patent/JP5789009B2/ja not_active Expired - Lifetime
- 2014-05-05 US US14/269,707 patent/US20150037353A1/en not_active Abandoned
-
2015
- 2015-02-12 CY CY20151100136T patent/CY1116147T1/el unknown
- 2015-04-13 JP JP2015081540A patent/JP2015171365A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE532073T1 (de) | Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels | |
| DE60336177D1 (de) | Auswertungsverfahren von Amplitudenwerten zur Ermittlung eines Slice-Level-Werts | |
| DE60026337D1 (de) | Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen | |
| ATE459578T1 (de) | Entsalzungsschiff sowie verfahren zur herstellung von entsalztem wasser | |
| ATE331217T1 (de) | Modulares fluorimeter und verfahren zu seiner verwendung zur erkennung eines oder mehrerer fluorophore | |
| ATE420204T1 (de) | Verfahren zur detektion von erkrankungen | |
| ATE458201T1 (de) | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 | |
| DE3882058D1 (de) | Immunoreaktives reagens, verfahren zu seiner herstellung und seine verwendung zur bestimmung einer immunoreaktiven spezies. | |
| DE69523116D1 (de) | Verbessertes Verfahren zur kolorimetrischen Bestimmung der Konzentration der weissen Blutzellen in einer biologischen Flüssigkeit | |
| ATE430812T1 (de) | Materialien und verfahren zum einfangen von krankheitserregern und zur abtrennung von aurintricarbonsäure aus einer probe | |
| DE60217351D1 (de) | Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens | |
| DE602005019475D1 (de) | Verfahren zur Bestimmung einer anfänglichen Nukleinsäurekonzentration anhand von real-time Amplifikationsdaten | |
| DE60335276D1 (de) | Verfahren zur umrechnung von venösen blutwerten in arterielle blutwerte, system zur verwendung der methode | |
| DE112006002354A5 (de) | Analyseverfahren zur Bestimmung eines Organfunktionsparameters unter bevorzugter Verwendung einer wässrigen C-Methacetin-Lösung | |
| DE59009364D1 (de) | Verfahren zur quantitativen Bestimmung zumindest eines chemischen Parameters eines Probenmediums. | |
| ATE482398T1 (de) | Verfahren zur stratifizierung von herzinsuffizienz | |
| DE60020347D1 (de) | Verfahren zur herstellung einer matrize von chemischen oder biologischen molekülsequenzen für eine chemische oder biologische analysevorrichtung | |
| EP1669761A3 (de) | Verfahren zur automatischen Bestimmung des endogenen Thrombinpotenzials | |
| ATE423310T1 (de) | Verfahren und mittel zur bestimmung von gesamtsäure | |
| EP1605260A3 (de) | Verfahren und Testkit zur Bestimmung des organisch gebundenen Kohlenstoffs (TOC) | |
| ATE465411T1 (de) | Verfahren zur bestimmung von anfälligkeit einer person zur infektion | |
| ATE470154T1 (de) | Verfahren zur bewertung von insulinresistenz | |
| RU2003134132A (ru) | Способ экспресс-определения кальция в моче | |
| ATE483983T1 (de) | Verfahren zur diagnose von chronischem stress und verwandten erkrankungen | |
| ATE509277T1 (de) | Verfahren zur bestimmung von 1,5-anhydroglucitol unter verwendung von vollblut |